Biosimilar Therapeutic Peptides Market Set To Grow From $3.89 Billion In 2026 To $6.11 Billion By 2030 At A CAGR Of 11.9%
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Biosimilar Therapeutic Peptides Market Forecast: What Market Value Is Expected By 2030?
The market for biosimilar therapeutic peptides has experienced swift expansion in recent years. Projected to rise from $3.5 billion in 2025 to $3.9 billion in 2026, it reflects a compound annual growth rate (CAGR) of 11.5%. This historical growth has been driven by factors such as the restricted supply of biosimilar peptides, a dependence on novel peptide treatments, a rising incidence of cancer and metabolic conditions, heightened awareness regarding peptide-based therapies, and advancements in parenteral delivery techniques.
The market for biosimilar therapeutic peptides is projected to experience significant expansion over the coming years. By 2030, its value is anticipated to reach $6.11 billion, registering a compound annual growth rate (CAGR) of 11.9%. This upward trajectory during the forecast period is driven by several factors, including the launch of combination and long-acting peptides, the scaling up of generic peptide manufacturing, a greater uptake of transdermal delivery systems, increased funding for peptide research and development, and higher global healthcare spending on peptide-based treatments. Notable trends shaping this period involve a heightened demand for biosimilar therapeutic peptides in oncology, a broader application of peptide therapies for metabolic and cardiovascular conditions, a shift toward long-acting and combination peptide formulations, the growing use of parenteral and transdermal administration methods, and a strategic emphasis on cost-effective generic peptides to improve accessibility in emerging economies.
Download A Free Sample Report For Comprehensive Market Insights:
Biosimilar Therapeutic Peptides Market Industry Drivers: What Is Driving Revenue Growth?
The growing incidence of chronic diseases is anticipated to propel the biosimilar therapeutic peptide market. These long-lasting health conditions require continuous care and management over extended periods, often spanning many years or a lifetime. As the number of such cases rises, there is an increasing need for affordable treatment options, positioning biosimilar therapeutic peptides as a cost-effective solution that can enhance patient access and support the sustainability of healthcare systems. Market expansion is further supported by favorable regulatory frameworks and accumulating clinical evidence. For example, in April 2025, the US Centers for Disease Control and Prevention (CDC) reported that in 2023, approximately 194 million American adults—representing 76.4%—had at least one chronic condition. This prevalence varied by age group: 59.5% among young adults, 78.4% among those in midlife, and 93.0% among older adults. Consequently, the increasing burden of chronic diseases is likely to drive growth in the biosimilar therapeutic peptides market.
Biosimilar Therapeutic Peptides Market Segment Analysis: What Are The Major Market Categories?
The biosimilar therapeutic peptides market covered in this report is segmented –
1) By Type: Innovative, Generic
2) By Route Of Administration: Parenteral Route, Transdermal Route, Other Route Of Administrations
3) By Application: Cancer, Cardiovascular, Central Nervous Systems, Metabolic Disorders, Infection, Hematological Disorders, Gastrointestinal Disorders, Dermatology, Respiratory Disorders
Subsegments:
1) By Innovative: Long-Acting Peptides, Combination Peptides
2) By Generic: Monoclonal Antibodies, Hormones, Enzymes
Biosimilar Therapeutic Peptides Market Growth Trends: What Is Influencing The Future Outlook?
Key players in the biosimilar therapeutic peptide market are advancing a research platform focused on streamlining peptide synthesis, boosting manufacturing effectiveness, and upholding consistent quality standards from initial discovery through full-scale commercialization. Known as the Biodrug Design Accelerator, this system is designed to oversee research workflows in peptide drug discovery—an area widely seen as a promising frontier in novel drug development. In May 2023, for example, Fujitsu Limited, a US-based toy manufacturing and entertainment firm, introduced the Biodrug Design Accelerator platform to expedite peptide drug discovery research. This platform aids pharmaceutical scientists by enhancing and accelerating peptide drug development through iterative cycles of design, synthesis, testing, and analysis (DMTA), thereby facilitating faster and smarter design of peptide drug candidates and fostering clearer communication among researchers about synthesis and testing procedures.
Biosimilar Therapeutic Peptides Market Leading Companies Driving Competitive Growth
Major companies operating in the biosimilar therapeutic peptides market are Pfizer Inc., Merck & Co. Inc., Novartis AG, Sanofi SA, Takeda Pharmaceuticals Co. Ltd., Eli Lilly and Company, Novo Nordisk A/S, Apotex Inc., Teva Pharmaceuticals Industries Ltd., Sandoz International GmbH, Lonza Inc., Stada Arzneimittel AG, Ipsen S.A, Biocon Biopharmaceuticals Pvt. Ltd., Dr. Reddy’s Laboratories Ltd., Alvogen Pharma US Inc., Corden Pharma GmbH, Bachem Holding AG, PolyPeptide Laboratories Ltd.
Access The Complete Biosimilar Therapeutic Peptides Market Report:
Biosimilar Therapeutic Peptides Market Global Footprint: Which Region Holds Market Leadership?
North America was the largest region in the biosimilar therapeutics peptides market in 2025. Middle East is expected to be the fastest growing region in the biosimilar therapeutic peptides market report during the forecast period. The regions covered in the biosimilar therapeutic peptides market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
